Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055861 · ClinicalTrials.gov registry record · Phase 2
Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT00055861: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00055861 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055861, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This phase II trial is to see if combining bevacizumab with docetaxel works in treating women who have locally advanced or metastatic breast cancer. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG docetaxel
- BIOLOGICAL bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2002-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055861
The ClinicalTrials.gov registry entry for NCT00055861 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00055861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00055861 about?
NCT00055861 is a clinical study titled "Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer". This phase II trial is to see if combining bevacizumab with docetaxel works in treating women who have locally advanced or metastatic breast cancer. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevaciz...
What is the current status of trial NCT00055861?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2002-07.
What interventions are being tested in trial NCT00055861?
The interventions under investigation include: laboratory biomarker analysis (OTHER), docetaxel (DRUG), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00055861?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.